德氮吡格及其衍生物抗肿瘤研究进展  

Research progress on anti-tumor effect of TNBG and its derivatives

作　　者：陈洁忠[1] 郑小红[2] 余瑜[3] CHEN Jiezhong;ZHENG Xiaohong;YU Yu(Department of Medical Nursing,Jiyuan Vocational and Technical College,Henan Jiyuan 459000,China;School of Pharmacy,Chongqing Medical and Pharmaceutical College,Chongqing 401331,China;College of Pharmaceutical Science,Chongqing Medicinal University,Chongqing 400016,China)

机构地区：[1]济源职业技术学院医学护理系,河南济源459000 [2]重庆医药高等专科学校药学院,重庆401331 [3]重庆医科大学药学院,重庆400016

出　　处：《现代肿瘤医学》2023年第13期2557-2562,共6页Journal of Modern Oncology

基　　金：国家自然科学基金项目(编号:30171070,30371632,30772595)。

摘　　要：脂代谢在肿瘤发展和侵袭中有至关重要的作用,已成为肿瘤细胞最重要的代谢标志之一。过氧化物酶体增殖物激活受体γ(peroxisome proliferator activated receptorγ,PPARγ)配体或激动剂对多种肿瘤均有良好的抗肿瘤作用。德氮吡格是自主研发的创新结构抗肿瘤药,体内外实验表明其抗肿瘤作用显著,呈现非细胞毒性,已证实PPARγ是其作用靶点。本文对德氮吡格及其衍生物的抗肿瘤作用及其机制进行综述。Lipid metabolism plays an important role in tumor development and invasion,and has become one of the most important metabolic markers of tumor cells.PPARγligands or agonists have good anti-tumor effects on a variety of tumors.TNBG is an innovative anti-tumor drug developed independently.In vitro and in vivo experiments show that it has significant anti-tumor effect,presenting non cytotoxicit.It has been confirmed that PPARγis its target.In this paper,the anti-tumor effects and mechanisms of TNBG and its derivatives are reviewed.

关 键 词：德氮吡格 肿瘤 药物 脂代谢 

分 类 号：R730.5[医药卫生—肿瘤]